Modulation of the Immune Response in Critical Illness/Injury

  • Lesley Doughty
Part of the Molecular and Cellular Biology of Critical Care Medicine book series (MCCM, volume 3)


The systemic inflammatory response is elicited in a multitude of clinical scenarios including infection, tissue injury (surgical or traumatic), ischemia-reperfusion, post-cardiopulmonary bypass, as well as autoimmune phenomena. There are many factors capable of modulating the magnitude and quality of the immune response during critical illness/injury. Some factors precede critical illness/injury such as chronic poor nutrition, chronic stress (physiologic and/or psychologic), and underlying infectious disease (chronic and acute). Other factors become important modulators during a critical illness/injury including acute stress, infection, tissue injury, poor nutrition, and pharmacologic agents not usually associated with immunomodulation.


Septic Shock Systemic Inflammatory Response Syndrome Multiple Organ Dysfunction Syndrome Cecal Ligation Abdominal Aortic Aneurysm Repair 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kox W, Volk T, Kox S, and Volk H. Immunomodulatory therapies in sepsis. Intensive Care Med. 2000. 26:S124-S128.Google Scholar
  2. 2.
    Volk H, Reinke P, and Docke WD. Immunologic monitoring of the inflammatory process: Which variable? When to assess? Eur J Surg. 1999. 584:70–72.Google Scholar
  3. 3.
    Kohm A and SandersV. Norepinephrine: A messenger from the brain to the immune system. Immunol Today. 2000. 21(11):539–542.PubMedGoogle Scholar
  4. 4.
    Chikanza IC and Grossman AB. Neuroendocrine mechanisms in rheumatic diseases. Rheum Dis Clin North Am. 2000. 26(4):693–711.Google Scholar
  5. 5.
    Torpy D and Chrousos GP. Stress and critical illness: The integrated immune/hypothalamic-pituitary-adrenal axis response. J Intensive Care Med. 1997. 12:225–238.Google Scholar
  6. 6.
    Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995. 332(20):1351–1362.PubMedGoogle Scholar
  7. 7.
    Chrousos GP. Therapeutic and clinical implications of systemic allergic inflammation. J Allergy Clin Immunol. 2000. 106(5):S275-S279.Google Scholar
  8. 8.
    Elenkov IJ and Chrousos G. Stress hormones, Th1/Th2 patterns, pro-anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab. 1999. 10:359–368.PubMedGoogle Scholar
  9. 9.
    Webster E, Torpy D, Elenkov IJ, and Chrousos GP. Corticotropin-releasing hormone and inflammation. Ann NY Acad Sci. 1998. 840:21–32.PubMedGoogle Scholar
  10. 10.
    Webster E, Elenkov IJ, and Chrousos GP. The role of corticotropin-releasing hormone in neuroendocrine-immune interactions. Mol Psychiatry. 1997. 2(5):368–372.PubMedGoogle Scholar
  11. 11.
    Radulovic M, Dautzenberg FM, Sydow S, Radulovic J, and Spiess J. Corticotropin-releasing factor receptor 1 in mouse spleen: Expression after immune stimulation and identification of receptor-bearing cells. J Immunol. 1999. 162:3013–3021.PubMedGoogle Scholar
  12. 12.
    Blalock JE. Proopiomelanocortin and the immune-neuroendocrine connection. Ann NY Acad Sci. 1999. 885:161–172.PubMedGoogle Scholar
  13. 13.
    Marriott I and Bost KL. Il-4 and IFN-γ up-regulate substance P receptor expression in murine peritoneal macrophages. J Immunol. 2000. 165:182–191.PubMedGoogle Scholar
  14. 14.
    Lotz M, Vaughan J, and Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988. 241(4870):1218–1221.PubMedGoogle Scholar
  15. 15.
    Panerai,A,Sacerdote,P. Beta-endorphin in the immune system: a role at last? Immunol Today. 1997. 18(7):317–319.PubMedGoogle Scholar
  16. 16.
    Holzer P. Neurogenic vasodilatation and plasma leakage in the skin. Gen Phamacol. 1998. 30(1):5–11.Google Scholar
  17. 17.
    Serhan CN, Fierro IM, Chiang N, and Pouliot M. Cutting edge: Nociceptin stimulates neutrophil Chemotaxis and recruitment: Inhibition by aspirin-triggered-15-Epi-lipoxin A41 J Immunol. 2001. 166:3650–3654.PubMedGoogle Scholar
  18. 18.
    Ben-Eliyahu S, Shakhar G, Page G, Stefanski V, and Shakhar K. Suppression of NK cell activity and of resistance to metastasis by stress: A role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation. 2000. 8(3):154–164.PubMedGoogle Scholar
  19. 19.
    Shakhar G and Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol. 1998. 160(7):3251–3258.PubMedGoogle Scholar
  20. 20.
    van der Poll T, Coyle SM, Barbosa K, Braxton CC, and Lowry S. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 1996. 97:713–719.PubMedGoogle Scholar
  21. 21.
    van der Poll T, Calvano SE, Kumar A, Coyle SM, and Lowry S. Epinephrine attenuates down-regulation of monocyte tumor necrosis factor receptors during human endotoxemia. J Leukoc Biol. 1997. 61:156–160.PubMedGoogle Scholar
  22. 22.
    Szabo C, Hasko G, Zingarelli B, Nemeth Z, Salzman A, Kvetan V, Pastores S, and Vizi E. Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology. 1997. 90:95–100.PubMedGoogle Scholar
  23. 23.
    Siegmund B, Eigler A, Moeller J, Greten TF, Hartmann G, and Endres S. Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents. Eur J Pharmacol. 1997. 321:231–239.PubMedGoogle Scholar
  24. 24.
    Agarwal SK and Marshall GD. Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol. 2000. 105(1 Pt 1):91–98.PubMedGoogle Scholar
  25. 25.
    Sanders V, Baker RA, Ramer-Quinn D, Kasprowicz D, Fuchs BA, and Street N. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: Implications for cytokine production and B cell help. J Immunol. 1997. 158(9):4200–4210.PubMedGoogle Scholar
  26. 26.
    Ramer-Quinn D, Baker RA, and Sanders V. Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: A mechanism for selective modulation of T helper 1 cell cytokine production. J Immunol. 1997. 159(10):4857–4867.PubMedGoogle Scholar
  27. 27.
    Farmer P and Pugin J. Beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IκB/NF-κB pathway. Am J Physiol Lung Cell Mol Physiol. 2000. 279:L675-L682.PubMedGoogle Scholar
  28. 28.
    Abraham E, Kaneko DJ, and Shenkar R. Effects of endogenous and exogenous catecholamines on LPS-induced neutrophil trafficking and activation. Lung Cellular and Molecular Physiology. 1999. 276:L1-L8.Google Scholar
  29. 29.
    Spengler R, Allen RM, Remick D, Streiter R, and Kunkel S. Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol. 1990. 145:1430–1434.]PubMedGoogle Scholar
  30. 30.
    Laffon M, Lu L, Modelska K, Matthay M, and Pittet J. α-Adrenergic blockade restores normal fluid transport capacity of alveolar epithelium after hemorrhagic shock. AJP-Lung Cellular and Molecular Physiology. 1999. 277(4):L760-L768.Google Scholar
  31. 31.
    Perlstien R, Whitnall M, Abrams JS, Mougey E, and Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology. 1993. 132:946–952.Google Scholar
  32. 32.
    Perlstein R, Mougey E, and Jackson W. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res. 1991. 10:141–146.PubMedGoogle Scholar
  33. 33.
    Mastorakos G, Weber J, Magiakou M, Gunn H, and Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin 6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol and Metab. 1994. 79:934Google Scholar
  34. 34.
    Gadient RA and Patterson PH. Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: Roles in inflammation and injury. Stem Cells. 1999. 17(3):127–137.PubMedGoogle Scholar
  35. 35.
    Wang Z, Ren S, and Melmed S. Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology. 1996. 137(7):2947–2953.PubMedGoogle Scholar
  36. 36.
    Chesnokova V and Melmed S. Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflammation. Endocrinology. 2000. 141(11):4032–4040.PubMedGoogle Scholar
  37. 37.
    Chesnokova V, Auernhammer CJ, and Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology. 1998. 139(5):2209–2216.PubMedGoogle Scholar
  38. 38.
    Goehler LE, Gaykema RP, Nguyen K, Lee J, Tilders F, Maier S, and Watkins LR. Interleukin-1β in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems? J Neurosci. 1999. 19(7):2799–2806.PubMedGoogle Scholar
  39. 39.
    Fleshner M, Goehler LE, Schwarts B, McGorry M, Martin D, Maier S, and Watkins LR. Thermogenic and corticosterone responses to intravenous cytokines (IL-1beta and TNF-alpha) are attenuated by subdiaphragmatic vagotomy. J Neuroimmunol. 1998. 86(2):134–141.PubMedGoogle Scholar
  40. 40.
    Gaykema RP, Dijkstra I, and Tilders FJ. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology. 1995. 136(10):4717–4720.PubMedGoogle Scholar
  41. 41.
    Hansen M, Nguyen K, Fleshner M, Goehler LE, Gaykema RP, Maier S, and Watkins LR. Effects of vagotomy on serum endotoxin, cytokines, and corticosterone after intraperitoneal lipopolysaccharide. Am J Physiol Regul Integr Compar Physiol. 2000. 278:R331-R336.Google Scholar
  42. 42.
    Gaykema RP, Goehler LE, Tilders F, Bol JG, McGorry M, Fleshner M, Maier S, and Watkins L. Bacterial endotoxin induces Fos immunoreactivity in primary afferent neurons of the vagus nerve. Neuroimmunomodulation. 1998. 5:234–240.PubMedGoogle Scholar
  43. 43.
    Napolitano L, Faist E, Wichmann M, and Coimbra R. Immune dysfunction in trauma. Surg Clin North Am. 1999. 79(6):1385–1416.PubMedGoogle Scholar
  44. 44.
    Faist E, Schinkel C, and Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg. 1996. 20:454–459.PubMedGoogle Scholar
  45. 45.
    Neidhardt R, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, and Ertel W. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma. 1997. 42(5):863–871.PubMedGoogle Scholar
  46. 46.
    Hershman M, Cheadle WG, Wellhausen S, Davidson PF, and Polk H. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg. 1990. 77:204–207.PubMedGoogle Scholar
  47. 47.
    Sayeed M. Alterations in cell signaling and related effector functions in T lymphocytes in burn/trauma/septic injuries. Shock. 1996. 5(3):157–166.PubMedGoogle Scholar
  48. 48.
    Markewitz A, Faist E, Lang S, Hultner L, Weinhold C, and Reichart B. An imbalance in T-helper cell subsets alters immune response after cardiac surgery. Eur J Cardiothorac Surg. 1996. 10(1):61–67.PubMedGoogle Scholar
  49. 49.
    Markewitz A, Faist E, Weinhold C, Lang S, Endres S, Hultner L, and Reichart B. Alterations of cell-mediated immune response following cardiac surgery. Eur J Cardiothorac Surg. 1993. 7(4):193–199.PubMedGoogle Scholar
  50. 50.
    Wakefield C, Carey PD, Foulds S, Monson J, Guillou P. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg. 1993. 80(2):205–209.PubMedGoogle Scholar
  51. 51.
    Harris B and Gelfand J. The immune response to trauma. Semin Pediatr Surg. 1995. 4:77–82.PubMedGoogle Scholar
  52. 52.
    Svoboda P, Kantorova I, and Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma. 1994. 36:336–340.PubMedGoogle Scholar
  53. 53.
    Livingston D, Appel SH, Wellhausen S, Sonnenfeld G, and Polk HC. Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg. 1988. 123(11):1309–1312.PubMedGoogle Scholar
  54. 54.
    Christou NV, Meakins J, Gordon J, Yee J, Hassan-Zahraee M, Nohr C, Shizgal H, and MacLean L. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg. 1995. 222(4):534–546.PubMedGoogle Scholar
  55. 55.
    De AK, Kodys K, Pellegrini J, Yeh B, Furse RK, Bankey P, and Miller-Graziano C. Induction of global anergy rather than inhibitory Th2 lymphokines mediates posttrauma T cell immunodepression. Clin Immunol. 2000. 96(1):52–66.PubMedGoogle Scholar
  56. 56.
    Puyana J, Pellegrini J, De AK, Kodys K, Silva W, and Miller C. Both T-helper-1-and T-helper-2-type lymphokines are depressed in posttrauma anergy. J Trauma. 1998. 44(6):1037–1045.PubMedGoogle Scholar
  57. 57.
    Hensler T, Hecker H, Heeg K, Heidecke C-D, Bartels H, Barthlen W, Wagner H, Siewert J-R, and Holzmann B. Distinct mechanisms of immunosuppression as a consequence of major surgery. Infect Immun. 1997. 65(6):2283–2291.PubMedGoogle Scholar
  58. 58.
    Cheadle WG, Hershman M, Wellhausen S, and Polk H. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg. 1991. 161:639–645.PubMedGoogle Scholar
  59. 59.
    Ayala A, Ertel W, and Chaudry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock. 1996. 5(2):79–90.PubMedGoogle Scholar
  60. 60.
    Wichmann M, Ayala A, and Chaudry IH. Severe depression of host immune functions following closed-bone fracture, soft-tissue trauma, and hemorrhagic shock. Crit Care Med. 1998. 26:1372–1378.PubMedGoogle Scholar
  61. 61.
    Epstein J, and Brewlow MJ. Perspectives in pain management. Crit Care Med. 1999. 15(1):17–33.Google Scholar
  62. 62.
    Ayala A, Song G, Chung CS, Redmond K, and Chaudry I. Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin. Crit Care Med. 2000. 28: 2949–2955.PubMedGoogle Scholar
  63. 63.
    Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996. 24(7):1125–1128.PubMedGoogle Scholar
  64. 64.
    Bone RC. Immunologic Dissonance: A continuing evaluation in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ failure syndrome (MODS). Ann Intern Med. 1996. 125:680–687.PubMedGoogle Scholar
  65. 65.
    Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk H, and Kox W. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med. 1997. 3(6):678–681.PubMedGoogle Scholar
  66. 66.
    Payen D, Faivre V, Lukaszewicz A, and Losser MR. Assessment of immunological status in the critically ill. Minerva Anesthesiol. 2000. 66:351–357.Google Scholar
  67. 67.
    Kawasaki T, Ogata M, Kawasaki C, Tomihisa T, Okamoto K, and Shigematsu A. Surgical stress induces endotoxin hyporesponsiveness and an early decrease of monocyte mCD14 and HLA-DR expression during surgery. Anesth Analg. 2001. 92(5):1322–1326.PubMedGoogle Scholar
  68. 68.
    Ogata M, Okamoto K, Kohriyama K, Kawasaki T, Itoh H, and Shigematsu, A. Role of interleukin-10 on hyporesponsiveness of endotoxin during surgery. Crit Care Med. 2000. 28(9):3166–3170.PubMedGoogle Scholar
  69. 69.
    Nguyen N, Luketich J, Schatz S, Tran Q, Ho H, and Schauer P. Effect of open and laparoscopic surgery on cellular immunity in a swine model. Surg Laparosc Endosc Percutan Tech. 1999. 9(3):176–180.PubMedGoogle Scholar
  70. 70.
    LeBlanc-Louvry I, Coquerel A, Koning E, Maillot C, and Ducrotte P. Operative stress response is reduced after laparoscopic compared to open cholecystectomy: the relationship with postoperative pain and ileus. Dig Dis Sci. 2000. 45(9):1703–1713.Google Scholar
  71. 71.
    Karayiannakis AJ, Makri G, Mantzioka A, Karousos D, and Karatzas G. Systemic stress response after laparoscopic or open cholecystectomy: a randomized trial. Br J Surg. 1997. 84(4):467–471.PubMedGoogle Scholar
  72. 72.
    Schietroma M, Carlei F, Lezoche E, Agnifili A, Enang GN, Mattucci S, Minervini S, and Lygidakis N. Evaluation of immune response in patients after open or laparoscopic cholecystectomy. Hepatogastroenterology. 2001. 48(39):642–646.PubMedGoogle Scholar
  73. 73.
    Welborn M, Oldenburg H, Hess P, Huber T, Martin T, Rauwerda J, Wesdorp R, Espat JN, Copeland EM, Moldawer L, and Seeger, J. The relationship between visceral ischemia, proinflammatory cytokines, and organ injury in patients undergoing thoracoabdominal aortic aneurysm repair. Crit Care Med. 2000. 28(9):3191–3197.PubMedGoogle Scholar
  74. 74.
    Holzheimer R, Gross J, and Schein M. Pro- and anti-inflammatory cytokine-response in abdominal aortic aneurysm repair: a clinical model of ischemia-reperfusion. Shock. 1999. 11(5):305–310.PubMedGoogle Scholar
  75. 75.
    Oldenburg H, Burress Welborn M, Pruitt J, Boelens PG, Seeger J, Martin T, Wesdorp R, Rauwerda J, van Leeuwen P, and Moldawer L. Interleukin-10 appearance following thoraco-abdominal and abdominal aortic aneurysm repair is associated with the duration of visceral ischaemia. Eur J Vasc Endovasc Surg. 2000. 20(2):169–172.PubMedGoogle Scholar
  76. 76.
    Ziegenfuss T, Wanner G, Grass C, Bauer I, Schuder G, Kleinschmidt S, Menger M, and Bauer M. Mixed agonistic-antagonistic cytokine response in whole blood from patients undergoing abdominal aortic aneurysm repair. Intensive Care Med. 1999. 25(3):279–287.PubMedGoogle Scholar
  77. 77.
    Foulds S, Mireskandari M, Kalu P, Jackson W, Cheshire NJ, Mansfield A, and Schachter M. Visceral ischemia and neutrophil activation in sepsis and organ dysfunction. J Surg Res. 1998. 75(2):170–176.PubMedGoogle Scholar
  78. 78.
    McBride W, Armstrong MA, Crockard AD, McMurray T, and Rea J. Cytokine balance and immunosuppressive changes at cardiac surgery: contrasting response between patients and isolated CPB circuits. Br J Anaesth. 1995. 75(6):724–733.PubMedGoogle Scholar
  79. 79.
    Yamaguchi T, Murakami A, Fukahara K, Ueda T, Ichida F, Miyawaki T, and Misaki T. Changes in T-cell receptor subsets after cardiac surgery in children. Surg Today. 2000. 30(10):875–878.PubMedGoogle Scholar
  80. 80.
    Flohe S, Borgermann J, Domínguez RE, Majetschak M, Lim L, Kreuzfelder E, Obertacke U, Nast-Kolb D, and Schade F. Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock. 1999. 12(1):17–24.PubMedGoogle Scholar
  81. 81.
    Ramanathan J, Coleman P, and Sibai B. Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia. Anesth Analg. 1991. 73(6):772–779.PubMedGoogle Scholar
  82. 82.
    Tsuji H, Asoh T, Takeuchi Y, and Shirasaka C. Attenuation of adrenocortical response to upper abdominal surgery with epidural blockade. Br J Surg. 1983. 70(2):122–124.PubMedGoogle Scholar
  83. 83.
    Rosenfeld B, Beattie C, Christopherson R, Norris E, Frank S, Brewlow MJ, Rock P, Parker S, Gottlieb SO, Perler B, et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Perioperative Ischemia Randomized Anesthesia Trial Study Group. Anesthesiology. 1993. 79(3):435–443.PubMedGoogle Scholar
  84. 84.
    Perler B, Christopherson R, Rosenfeld B, Norris E, Frank S, Beattie C, and Williams, G. The influence of anesthetic method on infra-inguinal bypass graft patency: a closer look. Am Surg. 1995. 61(9):784–789.PubMedGoogle Scholar
  85. 85.
    Norman J and Fink GW. The effects of epidural anesthesia on the neuroendocrine response to major surgical stress: a randomized prospective trial. Am Surg. 1997. 63(1):75–80.PubMedGoogle Scholar
  86. 86.
    Naito Y, Tamai S, Shingu K, Shindo K, Matsui T, Segawa H, Nakai Y, and Mori K. Responses of plasma adrenocorticotropic hormone, Cortisol, and cytokines during and after upper abdominal surgery. Anesthesiology. 1992. 77(3):426–431.PubMedGoogle Scholar
  87. 87.
    Panerai A, Manfredi B, Granucci F, and Sacerdote P. The beta-endorphin inhibition of mitogen-induced splenocytes proliferation is mediated by central and peripheral paracrine/autocrine effects of the opioid. J Neuroimmunol. 1995. 58(1):71–76.PubMedGoogle Scholar
  88. 88.
    Wetzel M, Steele A, Eisenstein TK, Adler MW, Henderson E, and Rogers T. Mu-opioid induction of monocyte chemoattractant protein-1, RANTES, and IFN-gamma-inducible protein-10 expression in human peripheral blood mononuclear cells. J Immunol. 2000. 165(11):6519–6524.PubMedGoogle Scholar
  89. 89.
    Welters I, Menzebach A, Goumon Y, Langefeld T, Teschemacher H, Hemplemann G, and Stefano GB. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and mu(3) opiate receptor-dependent mechanism. J Neuroimmunol. 2000. 111:139–145.PubMedGoogle Scholar
  90. 90.
    Sacerdote P, Manfredi B, Gaspani L, and Panerai A. The opioid antagonist naloxone induces a shift from Type 2 to Type 1 cytokine pattern in BALB/cJ mice. Blood. 2000. 95(6):2031–2036.PubMedGoogle Scholar
  91. 91.
    Welters I, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes T, Hemplemann G, and Stefano GB. Morphine inhibits NF-kappa B nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism. Anesthesiology. 2000. 92:1677–1684.PubMedGoogle Scholar
  92. 92.
    Sacerdote P, Manfredi B, Mantegazza P, and Panerai A. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997. 121(4):834–840.PubMedGoogle Scholar
  93. 93.
    Moeniralam HS, Endert E, Ackermans MT, van Lanschot JJB, Sauerwein HP, and Romijn JA. The opiate sufentanil alters the inflammatory, endocrine, and metabolic responses to endotoxin in dogs. Am J Physiol. 1998. 275(3):E440-E447.PubMedGoogle Scholar
  94. 94.
    Vamvakas E and Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood. 2001. 97(5):1180–1195.PubMedGoogle Scholar
  95. 95.
    Blajchman MA, Dzik S, Vamvakas E, Sweeney J, and Snyder E. Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. Transfusion Medicine Reviews. 2001. 15(2):108–135.PubMedGoogle Scholar
  96. 96.
    Ghio M, Contini P, Mazzei C, Merlo A, Filaci G, Setti M, Indiveri F, and Puppo F. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: Do they play a role in autologous blood transfusion? Transfusion. 2001. 41(8):988–996.Google Scholar
  97. 97.
    Puppo F, Ghio M, Contini P, Mazzei C, and Indiveri F. Fas, Fas ligand, and transfusion immunomodulation. Transfusion. 2001. 31:416–418.Google Scholar
  98. 98.
    Chin-Yee I, Keeney M, Krueger L, Dietz G, and Moses G. Supernatant from stored red cells activates neutrophils. Transfus Med. 1998. 8(1):49–56.PubMedGoogle Scholar
  99. 99.
    Silvergleid A. Leukoreduction to prevent complications of blood transfusion. 2002.
  100. 100.
    Biffl W, Moore E, Offner P, Ciesla DJ, Gonzalez RJ, and Silliman C. Plasma from aged stored red blood cells delays neutrophil apoptosis and primes for cytotoxicity: abrogation by poststorage washing but not prestorage leukoreduction. J Trauma. 2001. 50:426–432.PubMedGoogle Scholar
  101. 101.
    Quattrocchi K, Frank EH, Miller C, MacDermott J, Hein L, Frey L, and Wagner F. Suppression of cellular immune activity following severe head injury. J Neurotrauma. 1990. 7(2):77–87.PubMedGoogle Scholar
  102. 102.
    Asadullah K, Woiciechowsky C, Docke WD, Egerer K, Know WJ, Vogel S, Sterry W, and Volk HD. Very low monocytic HLA-DR expression indicates high risk of infection-immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med. 1995. 2(4):184–190.PubMedGoogle Scholar
  103. 103.
    Wilson N, Gooding A, Peterson B,Bastian JF. Anergy in pediatric head trauma patients. Am J Dis Child. 1991. 145(3):326–329.PubMedGoogle Scholar
  104. 104.
    Meert K, Long M, Kaplan J, and Sarnaik A. Alterations in immune function following head injury in children. Crit Care Med. 1995. 23(5):822–828.PubMedGoogle Scholar
  105. 105.
    Asadullah K, Woiciechowsky C, Docke WD, Liebenthal C, Wauer H, Kox W, Volk HD, Vogel S, and von Baehr R. Immunodepression following neurosurgical procedures. Crit Care Med. 1995. 23:1976–1983.PubMedGoogle Scholar
  106. 106.
    Quattrocchi KB, Frank EH, Miller C, Amin A, Issel B, and Wagner,F. Impairment of helper T-cell function and lymphokine-activated killer cytotoxicity following severe head injury. J Neurosurg. 1991. 75(5):766–773.PubMedGoogle Scholar
  107. 107.
    Miller C, Quattrocchi K, Frank EH, Issel B, and Wagner F. Humoral and cellular immunity following severe head injury: review and current investigations. Neurol Res. 1991. 13(2):117–124.PubMedGoogle Scholar
  108. 108.
    Quattrocchi K, Frank EH, Miller C, Dull ST, Howard R, and Wagner F. Severe head injury: effect upon cellular immune function. Neurol Res. 1991. 13(1):13–20.PubMedGoogle Scholar
  109. 109.
    Csuka E, Morganti-Kossmann M, Lenzlinger P, Joller H, Trentz O, and Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, TNF-alpha, TGF-betal and blood-brain barrier function. J Neuroimmunol. 1999. 101(2):211–221.PubMedGoogle Scholar
  110. 110.
    Whalen M, Carlos TM, Kochanek P, Wisniewski S, Bell M J, Carcillo JA, Clark RS, DeKosky ST, and Adelson P. Soluble adhesion molecules in CSF are increased in children with severe head injury. J Neurotrauma. 1998. 15(10):777–787.PubMedGoogle Scholar
  111. 111.
    Woiciechowsky C, Schoning B, Cobanov J, Lanksch W, Volk H, and Docke WD. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma. 2002. 52(2):339–345.PubMedGoogle Scholar
  112. 112.
    Lenzlinger PM, Hans VH, Joller-Jemelka HI, Trentz O, Morganti-Kossmann MC, and Kossmann T. Markers for cell-mediated immune response are elevated in cerebrospinal fluid and serum after severe traumatic brain injury in humans. J Neurotrauma. 2001. 18(5):479–489.PubMedGoogle Scholar
  113. 113.
    Robertson C, Minamino N, Ruppel R, Kangawa K, Adelson P, Tsuji T, Wisniewski S, Ohta H, Janesko K, and Kochanek P. Increased adrenomedullin in cerebrospinal fluid after traumatic brain injury in children: A preliminary report. Acta Neurochir Suppl. 2000. 76:419–421.PubMedGoogle Scholar
  114. 114.
    Stahel P, Kossmann T, Joller H, Trentz O, and Morganti-Kossmann M. Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma. Neurosci Lett. 1998. 249(203):123–126.PubMedGoogle Scholar
  115. 115.
    Lenzlinger PM, Marx A, Trentz O, Kossman T, and Morganti-Kossman MC. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol. 2002. 122:167–174.PubMedGoogle Scholar
  116. 116.
    Woiciechowsky C, Schoning B, Lanksch W, Volk H, and Docke WD. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med. 1999. 77:769–780.PubMedGoogle Scholar
  117. 117.
    Woiciechowsky C, Assadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, Glockner F, Lanksch W, Volk HD, and Docke WD. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med. 1998. 4:808–813.PubMedGoogle Scholar
  118. 118.
    Wolk K, Docke WD, von Baehr V, Volk HD, and Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood. 2000. 96:218–223.PubMedGoogle Scholar
  119. 119.
    Ertel W, Kremer J, Kenney J, Steckholzer U, Jarrar D, Trentz O, and Schildberg F. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995. 85(5):1341–1347.PubMedGoogle Scholar
  120. 120.
    Ayala A, Chung CS, Xu Y, Evans TA, Redmond K, and Chaudry,IH. Increased inducible apoptosis in CD4+ T lymphocytes during polymicrobial sepsis is mediated by Fas ligand and not endotoxin. Immunology. 1999. 97(1):45–55.PubMedGoogle Scholar
  121. 121.
    Volk,H, Reinke,P,Docke,WD. Clinical Aspects: From systemic inflammation to “immunoparalysis”. Chem Immunol. 2001. 74:162–177.Google Scholar
  122. 122.
    Hotchkiss R, Tinsley K, Swanson P, Schmieg R, Hui J, Chang KC, Osborne D, Freeman BD, Cobb JP, Buchman T, and Karl I. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol. 2001. 166:6963Google Scholar
  123. 123.
    Hotchkiss R, Swanson P, Freeman BD, Tinsley K, Cobb JP, Matuschak G, Buchman T, and Karl I. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999. 27:1230PubMedGoogle Scholar
  124. 124.
    Lauw F, ten Hove T, Dekkers PE, de Jonge E, van Deventer S,and van der Poll T. Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. Infect Immun. 2000. 68(3):1014–1018.PubMedGoogle Scholar
  125. 125.
    Hafenrichter D, Roland C, Mangino M, and Flye MW. The Kupffer cell in endotoxin tolerance: Mechanisms of protection against lethal endotoxemia. Shock. 1994. 2(4):241–256.Google Scholar
  126. 126.
    West M, Manthei R, and Burbrick MP. Autoregulation of hepatic macrophage activation in sepsis. J Trauma. 1993. 34(4):473–479.PubMedGoogle Scholar
  127. 127.
    Hall MW and Carcillo JA. Immune paralysis and the state of immunologic dissonance in pediatric multiple organ dysfunction syndrome (MODS). 2001. 29:A20.Google Scholar
  128. 128.
    Schinkel C, Licht K, Zedier S, Schinkel S, Fuchs D, and Faist E. Perioperative treatment with human recombinant interferon-gamma: A randomized double-blind clinical trial. Shock. 2001. 16(5):329–333.PubMedGoogle Scholar
  129. 129.
    Presneill J, Harris T, Stewart A, Cade JF, and Wilson J. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med. 2002. 166(2):129–130.Google Scholar
  130. 130.
    Bilgin K, Yaramis A, Haspolat K, Tas M, Gunbey S, and Derman O. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 2001. 107(1):36–41.PubMedGoogle Scholar
  131. 131.
    Kox W, Bone RC, Krausch D, Docke WD, Kox S, Wauer H, Egerer K, Querner S, Asadullah K, von Baeher R, and Volk HD. Interferon gamma-lb in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med. 1997. 157(4):389–393.PubMedGoogle Scholar
  132. 132.
    Doughty L, Nguyen K, Durbin J, and Biron C. A role for IFN-alpha beta in virus infection-induced sensitization to endotoxin. J Immunol. 2001. 166:2658–2664.PubMedGoogle Scholar
  133. 133.
    Nguyen K and Biron C. Synergism for cytokine-mediated disease during concurrent endotoxin and viral challenges: roles for NK and T cell IFN-gamma production. J Immunol. 1999. 162:5238–5246.PubMedGoogle Scholar
  134. 134.
    Doughty LA, Chung C, Lomas J, Nguyen K, Biron C, Ayala A. Mechanisms of Viral Potentiation of Inflammation: IFNα Modulation of the Cytokine Response to Sepsis. Shock. 2001;15:104.Google Scholar
  135. 135.
    Bosisio D, Polentarutti N, Sironi M, Bernasconi S, Miyake K, Webb G, Martin M, Mantovani A, and Muzio M. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: A molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood. 2002. 99(9):3427–3431.PubMedGoogle Scholar
  136. 136.
    Schneider-Schaulies S, Bieback K, Avota E, Klagge I, and terMeulen V. Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunmodulation. J Mol Med. 2002. 80(2):73–85.PubMedGoogle Scholar
  137. 137.
    Schneider-Schaulies S, Niewiesk S, Schneider-Schaulies J, and terMeulen V. Measles virus induced immunosuppression: Targets and effector mechanisms. Curr Mol Med. 2001. 1(2):163–181.PubMedGoogle Scholar
  138. 138.
    Avota E, Avots A, Niewiesk S, Kane LP, Bommhardt U, ter Meulen V, and Schneider-Schaulies,S. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat Med. 2001. 7(6):725–731.PubMedGoogle Scholar
  139. 139.
    Atabani SF, Byrnes AA, Jaye A, Kidd M, Magnusen AF, Whittle H, and Karp CL. Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis. 2001. 184:1–9.PubMedGoogle Scholar
  140. 140.
    Morrison T, Mauser A, Wong A, Ting J, and Kenney S. Inhibition of IFN-γ signaling by an Epstien-Barr virus immediate-early protein. Immunity. 2002. 15:787–799.Google Scholar
  141. 141.
    Moutaftsi M, Mehl A, Borysiewicz LK, and Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood. 2002. 99(8):2913–2921.PubMedGoogle Scholar
  142. 142.
    Yao Z, Ray S, Wisen-Vandervelde A, Waggoner,S, and Hahn Y. Hepatitis C virus: Immunosuppression by complement regulatory pathway. Viral Immunol. 2001. 14(4):277–295.PubMedGoogle Scholar
  143. 143.
    Large M, Kittlesen D, and Hahn Y. Suppression of host immune response by the core protein of Hepatitis C virus: Possible implications for Hepatitis C virus persistence. J Immunol. 1999. 162:931–938.PubMedGoogle Scholar
  144. 144.
    Najarro P, Traktman P, and Lewis,J. Vaccinia virus blocks gamma interferon signal transduction: Viral VH1 phosphatase reverses Stat1 Activation. Journal of Virology. 2001. 75(7):3185–3196.PubMedGoogle Scholar
  145. 145.
    Wang F, Xing L, Liu M, Zhu C, Liu H, Wang,H, and Lei Z. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol. 2001. 7(4):537–541.PubMedGoogle Scholar
  146. 146.
    Guidotti, LG, and Chiu JH. To kill or to cure: Options in host defense against viral infection. Curr Opin Immunol. 1996. 8:483-Google Scholar
  147. 147.
    Zambrano-Villa S, Rosales-Borjas D, Carrero JC, and Ortiz-Ortiz L. How protozoan parasites evade the immune response. Trends Parasitol. 2002. 18(6):272–278.PubMedGoogle Scholar
  148. 148.
    Bogdan C and Rollinghoff M. The immune response to Leishmania: Mechanisms of parasite control and evasion. Int J Parasitol. 1998. 28(1):121–134.PubMedGoogle Scholar
  149. 149.
    Kotwal GJ. Microorganisms and their interaction with the immune system. J Leukoc Biol. 1997. 62(4):415–429.PubMedGoogle Scholar
  150. 150.
    Luder C, Gross U, and Lopes M. Intracellular protozoan parasites and apoptosis: Diverse strategies to modulate parasite-host interactions. Trends Parasitol. 2001. 17(10):480–486.PubMedGoogle Scholar
  151. 151.
    Wikel S and Alarcon-Chaidez FJ. Progress toward molecular characterization of ectoparasite modulation of host immunity. Veterinary Parasitology. 2001. 101:275–287.PubMedGoogle Scholar
  152. 152.
    Cooper PJ. Can intestinal helminth infections (geohelminths) affect the development and expression of asthma and allergic disease? Clin Exp Immunol. 2002. 128(3):398–404.PubMedGoogle Scholar
  153. 153.
    Wolk K, Docke WD, von Baehr V, Volk HD, and Sabat R. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: Importance in clinical immunoparalysis. Pathobiology. 1999. 67:253–256.PubMedGoogle Scholar
  154. 154.
    Sato S, Nomura F, Kawai T, Takeuchi O, Muhlradt P, Takeda K, and Akira S. Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol. 2000. 165(12):7096–7101.PubMedGoogle Scholar
  155. 155.
    Medvedev A, Kopydlowski K, and Vogel S. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol. 2000. 164(11):5564–5574.PubMedGoogle Scholar
  156. 156.
    Nomura F, Akashi S, Sakao Y, Sata S, Kawai T, Matsumoto M, Nakanishi K, Kimoto M, Miyake K, Takeda K, and Akira S. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface tolllike receptor 4 expression. J Immunol. 2000. 164(7):3476–3479.PubMedGoogle Scholar
  157. 157.
    Beigneaux A, Huang J, Le Contel C, Heremans H, and Parant M. Differential role of interferon-gamma in the potentiating effect of muramyl peptides for enhanced responses to lipopolysaccharide in mice: effect of cyclosporin A. J Interferon Cytokine Res. 1995. 15(4):359–365.Google Scholar
  158. 158.
    Parant M, Parant F, Vinit M, Jupin C, Noso Y,Chedid L. Priming effect of muramyl peptides for induction by lipopolysaccharide of tumor necrosis factor production in mice. J Leukoc Biol. 1990. 47(2):164–169.PubMedGoogle Scholar
  159. 159.
    Wang J, Jorgensen P, Ellingsen EA, Almiof M, Thiemermann C, Foster SJ, Aasen A, and Solberg R. Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. Shock. 2001. 16(3):178–182.PubMedGoogle Scholar
  160. 160.
    Field CJ, Johnson I, and Schley P. Nutrients and their role in host resistance to infection. J Leukoc Biol. 2002. 71:16–32.PubMedGoogle Scholar
  161. 161.
    Scrimshaw N and SanGiovanni J. Synergism of nutrition, infection, and immunity: An overview. Am J of Clin Nutr. 1997. 66(2):464S-477S.Google Scholar
  162. 162.
    Woodward B. Protein, Calories, and Immune Defenses. Nutr Rev. 1998. 56(1):S84-S92.PubMedGoogle Scholar
  163. 163.
    Palacio A, Lopez M, Perez-Bravo F, Monkeberg F, and Schlesinger L. Leptin levels are associated with immune response in malnourished infants. J Clin Endocrinol and Metab. 2002. 3040–3046.Google Scholar
  164. 164.
    Soliman A, ELZalabany MM, Salama M, and Ansari BM. Serum leptin concentrations during severe protein-energy malnutrition: correlation with growth parameters and endocrine function. Metabolism. 2000. 49(7):819–825.PubMedGoogle Scholar
  165. 165.
    Walrand S, Moreau K, Caldefied F, Tridon A, Chassagne J, Portefaix G, Cynober L, Beaufrere B, Vasson M, and Boirie Y. Specific and nonspecific immune responses to fasting and refeeding differ in healthy young adult and elderly persons. Am J Clin Nutr. 2001. 74(5):670–678.PubMedGoogle Scholar
  166. 166.
    Bhaskaram P. Micronutrient malnutrition, infection and immunity: An overview. Nutr Rev. 2002. 60(5):S40-S45.PubMedGoogle Scholar
  167. 167.
    Grunfeld C. Leptin and the immunosuppression of malnutrition. J Clin Endocrinol and Metab. 2002. 87(7):3038–3039Google Scholar
  168. 168.
    Ozata M, Ozdemir I, and Licinio J. Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol and Metab. 1999. 84:3686–3695.Google Scholar
  169. 169.
    Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, and Flier JS. Role of leptin in the neuroendocrine response to fasting. Nature. 1996. 382:250–252.PubMedGoogle Scholar
  170. 170.
    Lord G, Matarese G, Howard J, Baker R, Bloom S, and Lechler R. Leptin modulates the T cell immune response and reverses starvation-induced immunosuppression. Nature. 1998. 394:897-PubMedGoogle Scholar
  171. 171.
    Boden G, Chen X, Mozzoli M, and Ryan I. Effect of fasting on serum leptin in normal human subjects. J Clin Endocrinol and Metab. 1996. 81:3419–3423.Google Scholar
  172. 172.
    Matarese G, LaCava A, Sanna V, Lord,G, Lechler,R, Fontana S, and Zappacosta S. Balancing susceptibility to infection and autoimmunity: A role for leptin? Trends in Immunology. 2002. 23(4):182–187.PubMedGoogle Scholar
  173. 173.
    Matarese G, Sanna V, Di Giacomo A, Lord GM, Howard JK, Bloom SR, Lechler RI, Fontana S, and Zappacosta S. Leptin potentiates experimental autoimmune encephalomyelitis in SJL female mice and confers susceptibility to males. Eur J Immunol. 2001. 31:1324–1332.PubMedGoogle Scholar
  174. 174.
    ALKharfy KM, Kellum JA, and Matzke GR. Unintended immunomodulation: Part II. Effects of pharmacological agents on cytokine activity. Shock. 2000. 13(5):346–360.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Lesley Doughty
    • 1
  1. 1.Department of Pediatrics, Critical Care DivisionBrown University School of Medicine Rhode Island HospitalProvidenceUSA

Personalised recommendations